Resultado de búsqueda
17 de mar. de 2019 · We conducted the AUGUSTUS trial (a two-by-two factorial, randomized, controlled clinical trial) to assess the safety and efficacy of standard-dose apixaban as compared with a vitamin K...
- R.D. Lopes, G. Heizer, R. Aronson, A.N. Vora, T. Massaro, R. Mehran, S.G. Goodman, S.G. Goodman, S. ...
- 2019
15 de mar. de 2019 · Among patients with atrial fibrillation with recent ACS or PCI in the AUGUSTUS trial, adding apixaban to a P2Y 12 inhibitor resulted in lower bleeding compared with VKA with a lower rate of death or rehospitalization. In both arms, addition of aspirin resulted in greater bleeding without any difference in efficacy.
19 de ene. de 2021 · An open-label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial.
- Ziad Hijazi, John H. Alexander, Zhuokai Li, Daniel M. Wojdyla, Roxana Mehran, Christopher B. Granger...
- 2021
18 de abr. de 2019 · ClinicalTrials.gov/NCT02415400. In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y<sub>12</sub> inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of isch ….
- R.D. Lopes, G. Heizer, R. Aronson, A.N. Vora, T. Massaro, R. Mehran, S.G. Goodman, S.G. Goodman, S. ...
- 2019
2 de jul. de 2019 · AUGUSTUS is the first trial with a two-by-two factorial design in patients with atrial fibrillation (AF) on combined antithrombotic therapy after an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), respectively. 1 Thereby, it allows the independent evaluation of the effects of prescribing apixaban ...
- Thomas Gremmel, Patrick Sulzgruber, Alexander Niessner
- 2019
In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome...
1 de ago. de 2020 · The AUGUSTUS trial, with its 2×2 factorial design, demonstrated both a superiority of the double versus triple therapy and of the apixaban versus VKA regimens in terms of clinically significant bleedings, without significant differences in the incidence of ischemic events. 24 Closing the quartet of trials, the ENTRUST‐AF PCI trial ...
